Zhitong Finance App News, Keji Pharmaceutical-B (02171) announced that CT0596, a general-purpose CAR-T cell product targeting BCMA, completed the first patient infusion in a phase I registered clinical trial in China to treat patients with recurrent/refractory multiple myeloma (R/R MM). The results of the CT0596 IIT study were presented on a poster at the 2026 European Society of Hematology (EHA) Annual Meeting.

CT0596 is a general-purpose CAR-T cell therapy targeting BCMA. It was developed based on the Thank-U Plus® platform independently developed by Keji Pharmaceutical, and is currently undergoing phase I registered clinical trials in R/R MM. Early IIT results showed that CT0596 showed initial good safety and encouraging efficacy signals in R/R MM and primary plasma cell leukemia. The company also plans to further explore other plasma cell tumors and autoimmune diseases driven by autoreactive plasma cells.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.